David Goeddel

David V.
Goeddel was the founder of Tularik, Inc., founded in 1991, where the title held was Chief Executive Officer from 1996 to 2004.
Dr. Goeddel was the founder of Nurix Therapeutics, Inc., founded in 2009, where the title held was Director from 2009 to 2016.
Current jobs include Chairman at Surrozen Operating, Inc., Chairman at Hexagon Bio, Inc. since 2020, Chairman at A2 Biotherapeutics, Inc., Partner & Chairman at TCG Labs-Soleil, Member at National Academy of Sciences, Member at American Academy of Arts & Sciences, Partner at The Column Group LLC since 2007, General Partner at Ponoi Capital LP, and General Partner at Ponoi Capital II LP.
Former jobs include Chairman at Igenica Biotherapeutics, Inc., Chairman at Peloton Therapeutics, Inc., Chairman at NGM Biopharmaceuticals, Inc. from 2010 to 2018, Director-Molecular Biology at Genentech, Inc. from 1978 to 1993, Director at Neurona Therapeutics, Inc., Independent Director at Tenaya Therapeutics, Inc. from 2025 to 2026, Director at Constellation Pharmaceuticals, Inc., Director-Molecular Biology at Genetech AB from 1978 to 1993, Director at Flexus Biosciences, Inc., Independent Director at Rapt Therapeutics, Inc. from 2015 to 2020, Director at Surrozen, Inc. from 2017 to 2021, Director at Nura Bio, Inc., Director at Exonics Therapeutics, Inc., Senior Vice President-Scientific at Amgen, Inc. from 2004 to 2006, and Advisory Board at Velia, Inc. Education includes undergraduate degree from the University of California San Diego in 1972 and doctorate from The University of Colorado in 1977.